BeiGene Ltd. ADR | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
11,160.50
12,984.10
8,810.50
1,067.90
239,195.90
1,554
Cost of Goods Sold (COGS) incl. D&A
-
-
-
-
9,596.50
303
Gross Income
-
-
-
-
229,599.40
1,251
SG&A Expense
14,957.80
27,128.60
63,976.30
115,988.00
328,390.50
6,783
EBIT
5,391.10
15,695.40
56,709.80
116,825.30
98,791.10
5,531
Unusual Expense
60.10
122.50
1,824.90
1,511.00
-
-
Non Operating Income/Expense
110.10
205.20
909.40
970.10
11,540.00
16
Interest Expense
3,158.50
3,538.10
1,228.20
-
4,121.90
-
Pretax Income
7,902.90
18,473.50
57,066.60
118,924.10
91,373.00
5,407
Income Tax
-
-
-
53.90
2,242.60
124
Consolidated Net Income
7,902.90
18,473.50
57,066.60
118,978.00
93,615.60
5,283
Net Income
7,502.40
18,206.60
57,066.60
118,978.00
93,420.90
5,281
Net Income After Extraordinaries
7,502.40
18,206.60
57,066.60
118,978.00
93,420.90
5,281
Net Income Available to Common
7,502.40
18,206.60
57,066.60
118,978.00
93,420.90
5,281
EPS (Basic)
1.04
2.33
6.76
3.89
2.22
7.33
Basic Shares Outstanding
31,268.10
31,268.10
8,507.50
31,047.70
41,783.50
721
EPS (Diluted)
0.24
0.58
6.71
3.83
2.24
7.33
Diluted Shares Outstanding
31,268.10
31,268.10
8,507.50
31,047.70
41,783.50
721
EBITDA
3,797.30
14,144.50
55,165.80
114,920.20
94,185.50
5,454
Non-Operating Interest Income
2.00
39.80
1,786.90
382.20
-
109
Minority Interest Expense
400.40
267.00
-
-
194.70
2

About BeiGene

View Profile
Address
Zhongguancun Life Science Park
Beijing Beijing 102206
China
Employees -
Website http://www.beigene.com
Updated 07/08/2019
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V.